

Special Issue

Skin Cancers: Biomarkers and Potential Therapeutic Targets

Message from the Guest Editors

Skin malignancies such as highly lethal and aggressive melanoma and non-melanoma continue to represent a major health concern worldwide. So investigations related to disease risk factors, novel biomarkers for early detection or therapy efficacy monitoring present potential directions advancing both skin cancer diagnosis and treatment. Recent progresses in melanoma in terms of immunotherapies aimed at checkpoint inhibitors have opened new sophisticated avenues to be explored for skin cancer in general and melanoma management in particular. Refined technologies and clinical approaches for cancer detection and monitoring are useful tools in deciphering biomarkers and potential therapeutic biomolecules or cellular pathways.

Recently, the COVID-19 pandemic has impacted the dermato-oncology field by challenging diagnoses, therapeutic approaches, surveillance and the management of skin tumors. This pandemic has further led to the exploration of new research areas, resulting in novel biomarkers' disease panel at the border between cancer and infectious disease.

In this SI dedicated to skin cancers and hosted by the JPM, current findings in research and clinical approaches are welcome.

Guest Editors

Dr. Carolina Constantin

Prof. Dr. Sabina Zurac

Prof. Dr. Monica Neagu

Deadline for manuscript submissions

closed (10 April 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/111835

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).